Child Psychiatry
Child Psychiatry RSS Feed RSS

Motivational Interviewing With Teens About Weed

October 3, 2019
Elizabeth D’Amico, PhD
Elizabeth D’Amico, PhDElizabeth D’Amico, PhD

Senior Behavioral Scientist at RAND and member of the Motivational Interviewing Network of Trainers (MINT)

Dr. D’Amico has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Child psychiatrists can learn and use motivational interviewing to help teens across a range of substance use disorders. In this QA we cover the efficacy, training and implementation of outpatient motivational interviewing for marijuana and other substance use with teens.
Read More

Update: Is Watching 13 Reasons Why Bad for Teens?

October 3, 2019
Kristen Gardner, PharmD
Kristen Gardner, PharmD Dr. Gardner has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In the March/April 2019 issue we unpacked a study on the popular Netflix series, 13 Reasons Why, which portrayed the bullying and suicide of a teenager. Although the program increased awareness of these issues, some clinicians argued that it glamorized suicide and would be detrimental to vulnerable viewers. In this issue we cover a follow up study examining the potential impact of the series on the suicide rate in teens.
Read More

Transcranial Magnetic Stimulation (TMS) for Depression in Children and Adolescents

June 11, 2019
With concerns about both safety and efficacy surrounding antidepressant use in children and adolescents, we are always looking for safe, effective treatments for our patients. Transcranial Stimulation (TMS) has been around for many years, and its use in youth is expanding. We examine the evidence of efficacy and potential side effects in youth and adolescent populations.
Read More

Medications for Depression

June 11, 2019
Martha J. Ignaszewski, MD
Martha J. Ignaszewski, MDMartha J. Ignaszewski, MD

Chief Fellow, Clinical Fellow in Psychiatry at Boston Children’s Hospital

Dr. Ignaszewski has disclosed that she has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we review the findings of placebo- controlled trials done over the past 10 years on depression in kids and the discuss the current recommendations for medication treatment of depression in children and adolescents.
Read More

Practical Approaches to Vetting Clinical Research

June 11, 2019
Darren B. Courtney, MD, FRCPC
Darren B. Courtney, MD, FRCPCDarren B. Courtney, MD, FRCPC

Staff Psychiatrist for the Youth Addictions and Concurrent Disorders Service at the Centre for Addiction and Mental Health (CAMH), Toronto, Ontario, Canada

Dr. Courtney has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

In this QA, we discuss how to use the PICOT method to efficiently frame the clinical questions that arise in everyday practice. We also examine the hierarchy in terms of the types of studies that are most useful for the busy clinician to look at and provide a corresponding table covering the categories of evidence for clinical practice.
Read More

FDA Approves Adhansia XR

June 11, 2019
Talia Puzantian, PharmD, BCPP and Joshua Feder, MD
Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In this article we discuss a newly FDA-approved formulation for ADHD. Adhansia XR, is a new formulation of extended-release methylphenidate approved by the FDA for the treatment of ADHD in patients 6 years and older.
Read More

First Non-Drug Treatment Approved by FDA for Treating Children With ADHD

June 11, 2019
Talia Puzantian, PharmD, BCPP and Joshua Feder, MD
Talia Puzantian, PharmD, BCPP Joshua Feder, MD Drs. Puzantian and Feder have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.
In the article we discuss the effectiveness and safety of the first non-drug treatment for ADHD in kids. The FDA has recently granted medical device approval for its external Monarch Trigeminal Nerve Stimulation (eTNS) System for treating kids with ADHD ages 7–12 who are not currently taking medications.
Read More
Carlat Total Access Subscriptions: Get access to every article on the website.

Complete access to every article you search on the website.

Shop for Total Access
Free Psychiatry Updates
The latest unbiased psychiatric information sent to your inbox.
Specify Your Interests
Featured Book
Featured Video
Featured Podcast
Recommended

About

Shop Online

Newsletters

Contact

carlat@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.